Novartis enhances data access

Share this article:

Novartis announced Wednesday that it upped its transparency initiative and that researchers will now be able to tap into patient-level data for drugs approved in the US and EU. The company also announced Wednesday that it was enhancing its Clinical Study Report summaries so the findings will be available in what the company described in a statement as “easy to understand consumer language” by the end of 2014.

Novartis said these summaries will also include “additional interpretation of data.”

The drugmaker is one of several companies that have touted their efforts to make data more accessible. Others include GlaxoSmithKline and J&J subsidiary Janssen.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.